Bicara Therapeutics (BCAX) Q2 FY26 earnings call

Bicara Therapeutics announced significant leadership transitions, including a new CEO, CFO, and other executive appointments, to prepare for the potential commercialization of its lead asset, Ficera. The company reported strong clinical data for Ficera in HPV-negative head and neck cancer, with the pivotal Phase III study on track for an interim analysis in mid-2027, and initiated an alternative dosing study to support future adoption. Financials reflect increased investment in clinical development and launch readiness.